NCT05829317View on ClinicalTrials.gov

Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 20, 2023

Primary Completion Date

March 1, 2028

Study Completion Date

July 1, 2028

Conditions
Critical IllnessNew Onset Atrial Fibrillation
Interventions
DRUG

Magnesium sulfate

Intravenous Magnesium sulfate

DRUG

Placebo

0.9% NaCl

Trial Locations (4)

L8N 1Y3

NOT_YET_RECRUITING

St Joseph's Healthcare Hamilton, Hamilton

K7L2V7

RECRUITING

Kingston Health Sciences Centre, Kingston

K1H 8L6

NOT_YET_RECRUITING

The Ottawa Hospital - General Campus, Ottawa

K1Y 4E9

NOT_YET_RECRUITING

The Ottawa Hospital - Civic Campus, Ottawa

All Listed Sponsors
collaborator

Southeastern Ontario Academic Medical Organization (SEAMO)

UNKNOWN

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Dr. Stephanie Sibley

OTHER